In our endocrine resistant breast cancer cell models, MYC inhibition increased both JNK activation and LC3II levels, with an associated increased inhibition of cell growth in glutamine-only conditions (Figure 8B; Figure 9M). This evidence concerns the gene MYC and breast carcinoma.